Association between hypersomnolence and the COVID-19 pandemic: The International COVID-19 Sleep Study (ICOSS)

The COVID-19 pandemic and related restriction measures have affected our daily life, sleep, and circadian rhythms worldwide. Their effects on hypersomnolence and fatigue remain unclear. The International COVID-19 Sleep Study questionnaire which included items on hypersomnolence such as excessive day...

Full description

Saved in:

Bibliographic Details
Published in:	Sleep medicine Vol. 107; pp. 108 - 115
Main Authors:	Sarkanen, Tomi, Partinen, Markku, Bjorvatn, Bjørn, Merikanto, Ilona, Benedict, Christian, Nadorff, Michael R., Bolstad, Courtney J., Espie, Colin, Matsui, Kentaro, Chung, Frances, Morin, Charles M., Wing, Yun Kwok, Penzel, Thomas, Macêdo, Tainá, Mota-Rolim, Sérgio, Holzinger, Brigitte, Plazzi, Giuseppe, De Gennaro, Luigi, Landtblom, Anne-Marie, Inoue, Yuichi, Sieminski, Mariuz, Leger, Damien, Dauvilliers, Yves
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-07-2023 The Author(s). Published by Elsevier B.V
Subjects:	Adult COVID-19 COVID-19 - complications COVID-19 - epidemiology Disorders of Excessive Somnolence - diagnosis Fatigue Fatigue - complications Fatigue - epidemiology Female Humans Hypersomnia ICOSS Male Pandemic Pandemics Post-Acute COVID-19 Syndrome Quality of Life Sleep Sleepiness COVID-19 ICOSS Fatigue Pandemic Hypersomnia Sleepiness
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The COVID-19 pandemic and related restriction measures have affected our daily life, sleep, and circadian rhythms worldwide. Their effects on hypersomnolence and fatigue remain unclear. The International COVID-19 Sleep Study questionnaire which included items on hypersomnolence such as excessive daytime sleepiness (EDS), and excessive quantity of sleep (EQS), as well as sociodemographic factors, sleep patterns, psychological symptoms, and quality of life was distributed in 15 countries across the world from May to September in 2020. Altogether responses from 18,785 survey participants (65% women, median age 39 years) were available for analysis. Only 2.8% reported having had COVID-19. Compared to before the pandemic, the prevalence of EDS, EQS, and fatigue increased from 17.9% to 25.5%, 1.6%–4.9%, and 19.4%–28.3% amid the pandemic, respectively. In univariate logistic regression models, reports of having a COVID-19 were associated with EQS (OR 5.3; 95%-CI 3.6–8.0), EDS (2.6; 2.0–3.4), and fatigue (2.8; 2.1–3.6). In adjusted multivariate logistic regression, sleep duration shorter than desired (3.9; 3.2–4.7), depressive symptoms (3.1; 2.7–3.5), use of hypnotics (2.3; 1.9–2.8), and having reported COVID-19 (1.9; 1.3–2.6) remained strong predictors of EDS. Similar associations emerged for fatigue. In the multivariate model, depressive symptoms (4.1; 3.6–4.6) and reports of having COVID-19 (2.0; 1.4–2.8) remained associated with EQS. A large increase in EDS, EQS, and fatigue occurred due to the COVID-19 pandemic, and especially in self-reported cases of COVID-19. These findings warrant a thorough understanding of their pathophysiology to target prevention and treatment strategies for long COVID condition. •Excessive daytime sleepiness, excessive quantity of sleep and fatigue were estimated in 15 countries during COVID-19 pandemic.•Prevalence of hypersomnolence symptoms and fatigue were high during COVID-19 pandemic.•Prevalence of hypersomnolence symptoms and fatigue were larger during the COVID-19 infection per se.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1389-9457 1878-5506 1878-5506
DOI:	10.1016/j.sleep.2023.04.024